FBInvestor
Stocks / Enanta Pharmaceuticals Inc
Institutional Ownership

Enanta Pharmaceuticals Inc

CUSIP 29251M106COMENTAQ1 2026

13D / 13G Filings
52
Schedule 13D/13G on record
Beneficial Filers
19
Distinct reporting persons
Largest Stake
18.0%
Max % of class reported
Institutional Holders
128
13F filers (latest quarter)

Beneficial Owners — Schedule 13D / 13G

52 filings · latest Feb 13, 2026

Export CSV — Pro
#FiledReporting PersonForm% of ClassSharesFiling
1Feb 13, 2026Deep Track Capital, LP13G/A6.8%1.96MSEC
2Feb 5, 2026Farallon Capital Partners, L.P.13G/A9.8%2.82MSEC
3Jan 20, 2026Integrated Core Strategies (Us) LLC13G/A11.0%670.4KSEC
4Nov 13, 2025Integrated Core Strategies (Us) LLC13G/A11.0%1.14MSEC
5Nov 7, 2025Janus Henderson Group PLC13G12.1%3.49MSEC
6Oct 9, 2025Deep Track Capital, LP13G5.3%1.48MSEC
7Apr 17, 2025Blackrock, Inc.13G/A7.8%1.67MSEC
8Feb 14, 2025Jay R. Luly, Ph.D.13D/A7.7%SEC
9Feb 11, 2025Farallon Capital Partners, L.P.13G/A9.9%2.11MSEC
10Jan 22, 2025Integrated Core Strategies (Us) LLC13G11.0%1.38MSEC

42 more beneficial-ownership filings on Premium

See the full Schedule 13D/13G history for Enanta Pharmaceuticals Inc.

Unlock full history

Top Institutional Holders (13F)

Largest reported positions · latest quarter

View all →